VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NHC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
NHCNational HealthCare Corporation
$216.40$3.4B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksNHCPrice Target
NHC logo

National HealthCare Corporation (NHC) Price Target Analysis

Analyst Rating:
Based on 0 analysts

No Target Data

NHC trades at Wall Street's consensus target of —.

Current Price$216.40
Average Target—
Low—
Median—
High—

Analyst Target Range

Forward P/E27.2x
(Growth Premium)
PEG Ratio1.18
(Fair)
Implied Growth+1.6%
(Low)
Analyst Spread—

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$216.40
Consensus—
High—
Low—

Consensus Scenario Assumptions

The base valuation assumes NHC achieves its forward estimates and maintains a stable P/E multiple of 27.2x. This scenario reflects the blended consensus of multiple Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.

Analyst Ratings

No analyst coverage available for NHC

Coverage appears once Wall Street estimates are published.

NHC Price Target Analysis

Updated July 8, 2026

As of July 8, 2026, National HealthCare Corporation (NHC) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $3.38B.

Analyst price targets range from a low of N/A to a high of N/A.

The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.

From a valuation perspective, NHC trades at a trailing P/E of 28.2x and forward P/E of 27.2x. The forward PEG ratio of 1.18 indicates reasonable valuation for growth. Analysts expect EPS to grow +1.6% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $234.83, with bear and bull scenarios of $147.94 and $309.41 respectively. Model confidence stands at 52/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside
+11.2%
Industry Consensus
Avg Forward P/E
34.3x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
CompanyMarket CapPriceTargetUpside PotentialRatingFwd P/EAnalysts
EHC logo
EHCEncompass Health Corporation
$11.0B$110.72$146.00
+31.9%
Buy18.4x26
PNTG logo
PNTGThe Pennant Group, Inc.
$1.4B$39.70$39.00
-1.8%
Buy29.3x7
ADUS logo
ADUSAddus HomeCare Corporation
$2.0B$105.97$122.00
+15.1%
Buy15.2x16
CCRN logo
CCRNCross Country Healthcare, Inc.
$427M$13.22$12.50
-5.4%
Hold142.9x14
SEM logo
SEMSelect Medical Holdings Corporation
$2.0B$16.51$17.75
+7.5%
Hold13.5x14
SGRY logo
SGRYSurgery Partners, Inc.
$2.2B$17.17$19.33
+12.6%
Buy40.0x22
CHE logo
CHEChemed Corporation
$6.6B$485.37$475.00
-2.1%
Hold19.9x9
HCSG logo
HCSGHealthcare Services Group, Inc.
$1.7B$24.39$24.50
+0.5%
Hold22.5x15
ENSG logo
ENSGThe Ensign Group, Inc.
$10.0B$170.87$222.33
+30.1%
Buy22.6x13
MCK logo
MCKMcKesson Corporation
$97.0B$807.33$994.86
+23.2%
Buy18.2x31

NHC — Frequently Asked Questions

Quick answers to the most common questions about buying NHC stock.

What is the NHC stock price target for 2026?

The consensus price target for NHC is $N/A, close to the current price of $216.4 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.

Is NHC a buy, sell, or hold?

NHC has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.

Is NHC stock overvalued or undervalued?

NHC trades at a forward P/E of 27.1518x, representing a moderate valuation. With analysts targeting $N/A (N/A% implied move), the stock appears close to fair value.

How high can NHC stock go?

The most bullish Wall Street analyst has a price target of $N/A for NHC, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. Our quantitative valuation model projects a bull case target of $309 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover NHC stock?

NHC is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the NHC stock forecast?

The 12-month NHC stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A". Our proprietary valuation model produces a base case fair value of $235, with bear/bull scenarios of $148/$309.

What is NHC's fair value based on fundamentals?

Our quantitative valuation model calculates NHC's fair value at $235 (base case), with a bear case of $148 and bull case of $309. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 52/100.

What is NHC's forward P/E ratio?

NHC trades at a forward P/E ratio of 27.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 28.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy NHC stock?

NHC appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do NHC price targets vary so much?

NHC analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground. Our model's $148-$309 range provides an independent fundamental perspective.

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare